Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

Musti Group will publish its Half-Year Financial Report for October 2022 – March 2023 on Thursday, 4 May 2023

Musti Group plc                        Press Release                        27 April 2023 at 9.00 a.m. Musti Group will publish its Half-Year Financial Report for October 2022 – March 2023 on Thursday, 4 May 2023 Musti Group will publish its Half-Year Financial Report for October 2022 – March 2023 on Thursday, 4 May 2023 at 8:30 a.m. EEST. The report will be available at https://www.mustigroup.com/investors/reports-and-presentations/ after publication. A webcast and an international telephone conference for analysts and media will be arranged on the publishing day at 2:00 p.m. EEST.

Continued strong growth

STOCKHOLM – April 27th, 2023 - ContextVision, a medical technology software company specializing in image processing and image analysis, today proudly presents their Q1 Report for 2023.  The robust growth continues and in the first quarter of 2023 the company saw a revenue of SEK 32.4 M (27.2), an increase of 19% and an EBITDA of SEK 13.1 M (9.2) an increase of 42%. “We are continuing to grow our core business significantly more than the growth of the industry overall, which is in line with our strategic ambition,” says Gerald Pötzsch, CEO of ContextVision. With the successful

Interim Report for the period January – March 2023

Applications for market approval of lecanemab submitted on three continents Events during the first quarter 2023 · On January 6, the FDA approved lecanemab (Leqembi™) via the accelerated approval pathway for the treatment of Alzheimer's disease · BioArctic’s partner Eisai has filed for full approval for lecanemab in the US, EU, Japan and China. The submissions have all been accepted for review with the ones in the US, Japan and China being granted priority review · The Prescription Drug User Fee Act (PDUFA) action date for full approval in the US is July 6, 2023 · The

News conference on Kojamo’s Interim Report for January–March 2023 on 11 May 2023

Kojamo plc Press Release, 27 April 2023 at 9:00 a.m. EESTNews conference on Kojamo’s Interim Report for January–March 2023 on 11 May 2023 Kojamo plc’s Interim Report for January–March 2023 will be published on Thursday, 11 May 2023 at approximately 2:00 p.m. EEST. News conference Kojamo will hold a news conference for institutional investors, analysts and media on 11 May 2023 at 3:00 p.m. EEST at its headquarters at Mannerheimintie 168A, Helsinki, Finland. The event will be hosted by Kojamo’s CEO Jani Nieminen and CFO Erik Hjelt, and it will be held in English. After the event, the

Invitation to presentation of Pagero’s interim report for Q1 2023

Pagero Group AB (publ) publishes interim report for January – March 2023 on 11 May 2023 at 07.30 CET and invites to a presentation of the report at 09:00 CET on the same day.Bengt Nilsson, CEO of Pagero, will present Pagero’s first quarter of 2023 in a webcast. It will be possible to submit questions in writing during the presentation, which will be answered at the end of the broadcast. Follow the presentation live: Link  For more information Bengt Nilsson, CEOBengt.nilsson@pagero.com Jan-Olof Ohlsson, CFOJan-olof.ohlsson@

Polygiene Group AB (publ.) Interim Report January 1 – March 31, 2023

Strong gross margin and break-even at EBITDA level despite lower sales Net sales for the quarter totaled MSEK 28.0 (45.1), corresponding to a 37.9 % decline compared to 2022. However, the gross margin was solid at 76.4 (67.1) %. The quarterly operating profit, (EBITDA), amounted to MSEK -0.2 (9.3) for an EBITDA margin of -0.6 (20.7) %. Cash flow was negative at MSEK -1.2.  The quarter in brief (January - March 2023) · Net sales amounted to MSEK 28.0 (45.1). There is an exchange rate impact of approximately 2 % in the quarter compared to last year · The gross margin was 76.4 (

NOTICE TO ATTEND THE ANNUAL GENERAL MEETING IN OSSDSIGN AB

The shareholders in OssDsign AB, reg. no. 556841-7546, are hereby given notice to attend the annual general meeting at 10:00 am on Wednesday 31 May 2023 at Setterwalls Advokatbyrå’s offices at address Sturegatan 10 in Stockholm. Registration for the meeting commences 30 minutes before the opening of the meeting. The board of directors has decided, pursuant to Chapter 7, Section 4, Paragraph 2 of the Swedish Companies Act and the company’s articles of association, to apply the possibility of proxy collection in conjunction with the general meeting (se section Proxy collection below for more

Transcom Holding AB (publ): Invitation to Transcom first quarter 2023 results presentation webcast

Transcom are pleased to invite you to their Q1 2023 financial update webcast on Thursday, May 11, at 9:00 am CET, following the release of Q1 2023 results at 8:00 am CET. The Q1 report and presentation will be available on https://www.transcom.com/global/about-us/investor-relations. Representing Transcom Jonas Dahlberg, President & CEO Snejana Koleva, CFO Presentation details Date/Time: Thursday, May 11, at 9:00 am CET Online Registration link: https://app.livestorm.co/transcom-holding/transcom-holding-ab-q1-2023-results-presentation Important note: Please register via

Interim Report January-March 2023

First quarter · Order intake amounted to SEK 1,617 (1,441) million, an increase of 12 percent · Net sales increased 7 percent to SEK 1,219 (1,135) million. Based on constant exchange rates, net sales increased 1 percent · EBIT amounted to SEK 182 (206) million and the EBIT margin was 15 (18) percent  · Earnings per share were SEK 1.52 (1.69) Outlook 2023 The Board of Directors’ opinion remains that consolidated net sales for 2023 will be at a level of SEK 5.5 billion.CEO comments We have had a good start to 2023 with order intake increasing 12 percent, driven by a

Viking Line: A stable first quarter

Viking Line Abp                   BUSINESS REVIEW                      27.04.2023, 9.00 AMA stable first quarter   JANUARY-MARCH 2023 (compared to January–March 2022)  · Sales amounted to EUR 93.9 M (EUR 58.8 M). · Other operating revenue was EUR 8.8 M (EUR 6.0 M). · Operating income totalled EUR -0.9 M (EUR -18.1 M). · Net financial items were EUR -3.5 M (EUR -2.2 M). · Income before taxes totalled EUR -4.4 M (EUR -20.3 M). · Income after taxes totalled EUR -3.7 M (EUR -16.2 M).   Provided that energy prices remain at current levels and taking into account

Embellence Group Interim Report Q1 2023

Stable profitability in a challenging marketFirst quarter 2023 · Net sales amounted to MSEK 197.5 (184.4), up 7.1% · Organic, currency adjusted growth of -3.1% · EBITA amounted to MSEK 27.1 (30.7), down -11.7% · Adjusted EBITA* amounted to MSEK 27.1 (32.8), down -17.3% · Net profit for the period amounted to MSEK 12.9 (24.8) and earnings per share for the period before dilution to SEK 0.57 (1.15) · Operating cash flow amounted to MSEK 2.2 (37.2) Significant events during the quarter · No significant events during the quarter *EBITA excluding acquisition costs

Peab renovates and extends upper secondary school in Helsinki

Peab has been commissioned to renovate the upper secondary school Lärkan in Helsinki. The customer is the City of Helsinki and the contract is worth EUR 18 million.The upper secondary school is a culturally historic valuable building from 1962 which has not yet undergone a complete renovation. This has left many original surfaces and constructions intact. The renovation, which comprises the building’s facades, windows, outer doors and constructions, will be carried out so that the school’s characteristic features are preserved. All technology and classroom equipment will be updated as well.

OssDsign reaches commercial milestone of 750 implants sold in Germany

Uppsala, April 27, 2023. OssDsign AB (publ.) today announces that the company has reached the commercial milestone of 750 implants sold in Germany since market entry, with a significant acceleration in sales during the last two years.Germany is one of the most important markets in Europe and, in recent years, OssDsign has considerably increased its sales efforts in Germany, resulting in a significant acceleration in sales. In addition to this, the company has successfully delivered on its strategic priority to increase operational efficiency and reduce lead time for OssDsign Cranial PSI.

Stille AB: Interim Report Q1 2023

Stille AB (publ) publishes the report for the first quarter of the business year 2023. ”Good start – strong sales growth and significantly improved operating cashflow”, summarizes President and CEO Torbjörn Sköld.Revenues increased in the first quarter by 17.5 percent to 72.4 (61.6) after strong growth from both business units. “I am satisfied to see such strong growth compared to previous year given that the first quarter last year was a record quarter”, comments Torbjörn Sköld. The gross profit amounted to 42.4 percent (44.8). Business unit Surgical Tables was affected by an

Norse Atlantic ASA: Ex. reverse share split today

Issuer name: Norse Atlantic ASA Ex. date: 27 April 2023 Type of corporate action: reverse share split Ratio: four (4) old shares give one (1) new share New ISIN: NO 0012885252This information is published in accordance with the requirements of the Continuing Obligations. For further information, please contact: Ben Boiling, CFO Phone: +47 912 40 945 Email: ben.boiling@flynorse.com About Norse Atlantic ASA: Norse Atlantic Airways is a new airline that offers affordable fares on long -haul flights, primarily between Europe and the United States. The company was

Orexo Interim Report Q1 2023

Focusing operations on Orexo´s strengths Q1 2023 highlights · Total net revenues of SEK 158.8 m (159.4) · EBITDA of SEK -41.1 m (2.8), EBITDA excluding legal costs and costs for non-repeating clinical trials, SEK 20.9 m (32.2)  · Net earnings of SEK -63.9 m (-23.6) · US Pharma segment (ZUBSOLV® US) net revenues of SEK 140.3 m (139.1), in local currency USD 13.5 m (14.8), US Pharma EBIT of SEK 74.3 m (84.0) · Cash flow from operating activities of SEK -61.6 m (-61.6), cash and invested funds of SEK 278.9 m (437.8) · Earnings per share before and after dilution amounted

Interim report January – March 2023

FIRST QUARTER · Revenues amounted to MSEK 482.8 (MSEK 476.1), an increase by 1 % compared to the same period last year. · Operating profit amounted to MSEK 155.7 (MSEK 208.5), a decrease by 25 %. · Profit after financial items amounted to MSEK 157.1 (MSEK 207.7), and profit after tax amounted to MSEK 123.7 (MSEK 168.5). · Cash flow from operating activities amounted to MSEK 244.6 (MSEK 236.4), and cash flow from investing activities amounted to MSEK -170.1 (MSEK -157.4). · By the end of the period cash amounted to MSEK 812.7 (MSEK 671.2). · Earnings per share before

OKEA first quarter 2023 trading update

(Trondheim, 27 April 2023) OKEA ASA (OSE: OKEA) will publish its financial report for the first quarter of 2023 on Thursday 4 May at 06:00 (CET). This trading update is provided to summarise production and sales volumes and related topics and updates for the quarter.(Amounts in parentheses refer to previous quarter) First quarter 2023 production and sales Unit Q1 2023 Q4 2022Total operating income MNOK 2,954 1,664Realised liquids price USD/boe* 77.7 95.2Realised gas price

JM Interim Report January–March 2023

Challenging housing market in weak economy  • Revenue increased to SEK 3,962m (3,854). • Operating profit decreased to SEK 417m (466). The operating margin decreased to 10.5 percent (12.1). • Profit before tax decreased to SEK 394m (450), and profit after tax decreased to SEK 311m (356). • Return on equity for the past twelve months amounted to 16.8 percent (22.6). • Earnings per share amounted to SEK 4.80 (5.20). • Consolidated cash flow including net investment in properties amounted to SEK 792m (273). • The number of residential units sold decreased to 479 (995)

Finnair Group Interim Report 1 January – 31 March 2023

Finnair Plc                  Interim Report                 27 April 2023 at 9.00 a.m. EEST Strong demand and well-progressed strategy implementation led to break-even result during seasonally weakest quarter. January – March 2023                                   · Earnings per share were -0.01 euros (-0.15)*. · Revenue increased by 73.8% to 694.7 million euros (399.8). · Comparable operating result was 0.9 million euros (-132.9). Operating result was 8.3 million euros (-164.9). · High fuel price had an adverse cost impact of c. 40 million euros** year-on-year. ·

SKF First-quarter report 2023: Strong organic sales and positive margin trend

Gothenburg, 27 April 2023 Rickard Gustafson, President and CEO: “Review of the first quarterI’m pleased to report a solid quarter with strong organic sales growth and a record high adjusted operating profit for a first quarter. In the period, we delivered an organic sales growth of more than 10%, with continued robust demand across all our regions. Most of our targeted high-growth segments contributed with double-digit growth, e.g. railway, renewable energy and aero­space. The adjusted operating profit improved to SEK 3,478 million (3,058), with an adjusted operating margin of

Midsona - Interim Report January-March 2023

Improved gross margin and continued strong cash flow January–March 2023 (first quarter)● Net sales amounted to SEK 974 million (972). ● EBITDA, before items affecting comparability, amounted to SEK 60 million (62), corresponding to a margin of 6.2 percent (6.4) and EBITDA amounted to SEK 55 million (62). ● Operating profit, before items affecting comparability, amounted to SEK 21 million (22), corresponding to a margin of 2.2 percent (2.3) and the operating profit amounted to SEK 16 million (22). ● The profit/loss for the period was SEK –6 million (12), corresponding to earnings/

Interim report Q1, January - March 2023

Summary January - March 2023• Net sales amounted to SEK 87.4 (75.6) million, an increase of 15.6 percent compared to the corresponding period last year. Currency-adjusted growth amounted to 11.0 percent.• EBIT amounted to SEK 8.2 (-0.2) million, corresponding to an EBIT margin of 9.3 (-0.3) percent.• Profit after tax amounted to SEK 6.7 (1.4) million.• Earnings per share before/after dilution amounted to SEK 0.36 (0.07).• Cash flow from operating activities increased to SEK 24.0 (5.5) million, in addition to the results for the period and driven primarily by a positive change in

Sobi publishes Q1 2023 report: Continued solid progress

Swedish Orphan Biovitrum AB (publ)  (Sobi®) today announced its reportfor the first quarter of 2023   First quarter 2023 •          Total revenue SEK 5,239 M (4,925), +6 per cent, -2 per cent at constant exchange rates (CER).[i] •          Haematology revenue SEK 2,815 M (2,499), +5 per cent at CER of which Elocta® SEK 1,196 M (1,024), +9 per cent at CER; Alprolix® SEK 514 M (419), +16 per cent at CER; Doptelet® SEK 475 M (593), -28 per cent at CER and Aspaveli®/Empaveli® SEK 95 M (4) •          Immunology revenue SEK 2,151 M (2,119), -9 per cent at

There are no items matching the current filter
There are no more items matching the current filter
Back to top